Cardlytics, Inc. (NASDAQ:CDLX – Get Free Report) CFO Alexis Desieno sold 8,854 shares of the firm’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $3.67, for a total transaction of $32,494.18. Following the transaction, the chief financial officer now owns 121,976 shares of the company’s stock, valued at approximately $447,651.92. This trade represents a 6.77 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Alexis Desieno also recently made the following trade(s):
- On Friday, November 15th, Alexis Desieno sold 25,118 shares of Cardlytics stock. The stock was sold at an average price of $3.43, for a total value of $86,154.74.
Cardlytics Price Performance
CDLX stock traded down $0.32 during trading on Monday, hitting $3.49. The company had a trading volume of 2,033,344 shares, compared to its average volume of 1,212,448. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. The company has a market cap of $177.37 million, a P/E ratio of -0.57 and a beta of 1.53. Cardlytics, Inc. has a fifty-two week low of $2.89 and a fifty-two week high of $20.52. The company has a fifty day moving average price of $3.93 and a two-hundred day moving average price of $4.85.
Analyst Upgrades and Downgrades
CDLX has been the topic of several research analyst reports. Craig Hallum upgraded shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 6th. Evercore ISI initiated coverage on Cardlytics in a research report on Friday, October 11th. They issued an “in-line” rating and a $4.00 target price on the stock. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Cardlytics in a report on Thursday, November 7th. One analyst has rated the stock with a sell rating, five have given a hold rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Cardlytics has an average rating of “Hold” and an average target price of $6.92.
Read Our Latest Stock Report on Cardlytics
Institutional Investors Weigh In On Cardlytics
Large investors have recently modified their holdings of the business. Atom Investors LP acquired a new stake in Cardlytics in the 3rd quarter valued at $33,000. XTX Topco Ltd acquired a new position in shares of Cardlytics in the 2nd quarter valued at approximately $107,000. SG Americas Securities LLC acquired a new stake in Cardlytics in the third quarter valued at about $45,000. Intech Investment Management LLC bought a new stake in shares of Cardlytics during the third quarter worth $47,000. Finally, Quest Partners LLC increased its position in Cardlytics by 160.4% in the 2nd quarter. Quest Partners LLC now owns 17,956 shares of the company’s stock valued at $147,000 after acquiring an additional 11,061 shares during the period. 68.10% of the stock is currently owned by institutional investors.
About Cardlytics
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
Featured Articles
- Five stocks we like better than Cardlytics
- Election Stocks: How Elections Affect the Stock Market
- Build-Your-Bowl Battle: CAVA, Chipotle, and Sweetgreen Face Off
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Insiders Are Loading Up: 3 Key Stock Picks for Investors
- Golden Cross Stocks: Pattern, Examples and Charts
- How Cigna Remains at the Top of the Health Insurance Food Chain
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.